Blackwell Kimberly 4

What Happened
Kimberly Blackwell, a director of Monte Rosa Therapeutics (GLUE), was granted an award of 25,800 derivative shares on June 11, 2026. The Form 4 lists the award at $0.00 (derivative security), indicating an option/award rather than an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-12 (timely filing).
• Transaction type/code: A (award/grant of derivative securities).
• Amount: 25,800 shares; reported price $0.00 (derivative).
• Vesting/exercise: Per footnote, the option vests and becomes exercisable in full on the earlier of (i) June 11, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service.
• Shares owned after transaction: Not specified in the provided summary of the filing.
• No indication of a 10b5‑1 plan, tax withholding, or immediate sale.

Context
This is a compensation/retention award to a board member (common for directors) rather than a purchase or sale. As a derivative award, it becomes exercisable only if/when it vests; it does not represent immediate cash proceeds or open‑market activity. Such grants are routine for director pay and should be viewed as compensation-related information rather than a direct bullish or bearish trade signal.